Population Pharmacokinetic Modeling of the Oral Calcitonin Gene-Related Peptide Receptor Antagonist Rimegepant in Adults.

ABSTRACT: Rimegepant is a small-molecule calcitonin gene-related peptide receptor antagonist approved for acute and preventive migraine treatment in adults, administered as an orally disintegrating tablet (ODT). A population pharmacokinetic analysis was performed to describe rimegepant's plasma concentration-time course and to estimate covariate effects on rimegepant exposure. The model was developed/evaluated in 3 stages using data from 11 phase 1 clinical studies, wherein rimegepant was administered orally to healthy adults, elderly people with stable chronic illness(es), adults with renal or hepatic dysfunction, and healthy adults with Japanese or Chinese ethnicity. Plasma concentration-time data were analyzed using nonlinear mixed effects modeling. A 2-compartment model with 4 transit compartmen

SUBMITTER: Comisar CM 

PROVIDER: S-EPMC12358308 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature